Hybridoma Cell Line Development
Hybridoma cell line development consists of four (4) phases including immunization, fusion, cloning and In vitro antibody production. Typically, 4 - 6 mg of soluble antigen is required to complete a protein or peptide based project. Upon successfully developing a panel of stable hybridoma cell lines, further characterization of secreted monoclonal antibodies and small-scale production is included at no additional cost. Complete documentation of all phases and a development summary is provided to clients at the conclusion of each project.
Communication with clients is of essential importance to Leinco Technologies’ quality development process. Project status reports are generated in real time and are available to clients on our secure internet project management system. Teleconferences are scheduled to discuss data and the next steps in each project.
Monoclonal Antibody Development